^
Association details:
| Biomarker: | KRAS G12C + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Impact of KRAS Mutation Subtype and Comutations across PD-L1 Levels in aNSCLC Patients Treated with (Chemo)Immunotherapy
Published date:
08/08/2023
Excerpt:
Patients with advanced(a) NSCLC starting frontline (chemo)immunotherapy...However, in the PD-L1-high subgroup, whereas KRASm was not associated with survival compared to KRASwt, G12V had worse rwOS than G12C...Within the PD-L1>50% subgroup, KRAS G12C was associated with better rwOS than KRAS G12V.
Source:
Title:
Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy
Published date:
03/15/2022
Excerpt:
Our aim in this hypothesis-generating pilot study was to evaluate whether the KRAS G12C variant may predict the efficacy of ICIs in advanced NSCLC patients with PD-L1 ≥ 50%....KRAS G12C mutant patients (N = 11/44) showed a significantly longer progression-free survival (PFS) at univariate and multivariate analyses (p = 0.03). The Kaplan-Meier plot of the PFS time-to-event supports that G12C positive patients have a longer time to progress...we tentatively conclude the KRAS G12C mutation should be considered in future trials as a predictive marker of prolonged response to first-line ICIs in NSCLC patients overexpressing PD-L1.
DOI:
10.3390/jcm11061627
Source:
Title:
1809P - Evaluation of KRAS mutation subtype on survival in patients with metastatic non-small cell lung cancer receiving immunotherapy
Published date:
09/13/2021
Excerpt:
...patients in the G12C group with high PD-L1 expression had significant benefit from ICI over other subtypes: ORR 65%, mPFS 23.5m. KRAS G12C mutated tumors had higher ORR and PFS than non-G12C mutations to ICI.
Source:
Title:
Impact of KRAS mutational variant on response to immunotherapy in metastatic NSCLC.
Published date:
05/19/2021
Excerpt:
98 KRAS mutant mNSCLC patients were treated with immune checkpoint inhibitors...the superiority in PFS was driven by the G12C mutants with high PD-L1 expression (n = 19): 26.8 months in G12C, PD-L1 high vs 4.7 months in G12C...The greatest benefit in PFS was observed in the subgroup with G12C mutation and high PD-L1 expression.
DOI:
10.1200/JCO.2021.39.15_suppl.e21127
